IMGS-501 / ImmunoGenesis - LARVOL DELTA

Preclinical Characterization of an Anti–HER2-STING Immune-Stimulator Antibody Conjugate in HER2+ Solid Tumor (EACR 2024) - "Here we describe DN028073, designed to selectively deliver our currently phase 1 clinical drug DN015089 (CTR20212462) to HER2+ cells through ADC format...In CT-26 tumor bearing immunocompetent mice, treatment with DN028073 (1mg/kg) treatment alone achieved strong antitumor activity better than treatment with Enhertu ® (10mg/kg)...In pharmacokinetics and pharmacodynamics, DN028073 has a preferable PK profile and can activate immune system via in intravenous (i.v.) and subcutaneous (s.c.) administration.Conclusion Preclinical strong antitumor activity and favorable drug-like properties have motivated clinical testing of STING-ISAC for novel immunotherapies. The potential of other new target delivery and new combination therapies might provide new choice for locally advanced or metastatic solid tumors."

IO biomarker • Preclinical • Oncology • Solid Tumor • STING

Preclinical Characterization of an Anti–HER2-STING Immune-Stimulator Antibody Conjugate in HER2+ Solid Tumor (EACR 2024) - "Here we describe DN028073, designed to selectively deliver our currently phase 1 clinical drug DN015089 (CTR20212462) to HER2+ cells through ADC format...In CT-26 tumor bearing immunocompetent mice, treatment with DN028073 (1mg/kg) treatment alone achieved strong antitumor activity better than treatment with Enhertu ® (10mg/kg)...In pharmacokinetics and pharmacodynamics, DN028073 has a preferable PK profile and can activate immune system via in intravenous (i.v.) and subcutaneous (s.c.) administration.Conclusion Preclinical strong antitumor activity and favorable drug-like properties have motivated clinical testing of STING-ISAC for novel immunotherapies. The potential of other new target delivery and new combination therapies might provide new choice for locally advanced or metastatic solid tumors."

IO biomarker • Preclinical • Oncology • Solid Tumor • STING

ImmunoGenesis CEO James Barlow to Present on Company's Immuno-Oncology Clinical Development Targeting Immune-Excluded, 'Cold' Cancers at BIO CEO & Investor Conference (PRNewswire) - "ImmunoGenesis...announced today that President and CEO James Barlow will present on the company and its multiple immune-oncology therapeutic development programs targeting immune-excluded cold cancers at the upcoming 2022 BIO CEO & Investor Conference...Evofosfamide....is on target to be in clinic in combination with immune checkpoint blockades in 2022."

Clinical • New trial • Gastrointestinal Cancer • Genito-urinary Cancer • Glioblastoma • Hematological Malignancies • Lung Cancer • Neuroendocrine Tumor • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Prostate Cancer • Renal Cell Carcinoma • Sarcoma • Solid Tumor

Data from ImmunoGenesis' Lead Programs Presented in Six Posters at Society for Immunotherapy of Cancer (SITC) Conference (PRNewswire) - "Posters Related to IMGS-501: For the first time, this study concluded that synthetic CDN STING agonists affect MDSC and M2 macrophage repolarization, in part through altering metabolism and c-Myc signaling. Lastly, the study demonstrated the potential for high-potency STING agonists to overcome resistance to checkpoint blockade in an aggressive orthotopic tumor model of pancreatic ductal adenocarcinoma....The study concluded that STING agonists prolong survival in human and murine orthotopic models of glioblastoma. This prolonged survival is associated with a decrease in immunosuppressive M2 functional markers in human tumor infiltrating myeloid populations."

Preclinical • Glioblastoma • Oncology • Pancreatic Ductal Adenocarcinoma • Solid Tumor